UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Clinical cancer research, 2015-09, Vol.21 (17), p.3870-3878

2015

Link zum Volltext

Verfügbarkeit prüfen

Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats

Journal of pharmacy and pharmacology, 2001-04, Vol.53 (4), p.569-577

2001

Link zum Volltext

Verfügbarkeit prüfen

Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9011-9011

2016

Link zum Volltext

Verfügbarkeit prüfen

Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3106-3106

2014

Link zum Volltext

Verfügbarkeit prüfen

Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3546-3546

2015

Link zum Volltext

Verfügbarkeit prüfen

A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2505-2505

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2504-2504

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-19-08

2015

Link zum Volltext

Verfügbarkeit prüfen

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8559-8559

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.703-703

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT211-CT211

2014

Link zum Volltext

Verfügbarkeit prüfen

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1016-1016

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C67-C67

2013

Link zum Volltext

Verfügbarkeit prüfen

IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3032-3032

2014

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of carcinogenesis by tea

Annual review of pharmacology and toxicology, 2002-01, Vol.42 (1), p.25-54

2002

Link zum Volltext

Verfügbarkeit prüfen

Urinary and Plasma Levels of Resveratrol and Quercetin in Humans, Mice, and Rats after Ingestion of Pure Compounds and Grape Juice

Journal of agricultural and food chemistry, 2004-02, Vol.52 (4), p.935-942

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability

Cancer epidemiology, biomarkers & prevention, 2002-10, Vol.11 (10), p.1025-1032

2002

Link zum Volltext

Verfügbarkeit prüfen

Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract

Cancer epidemiology, biomarkers & prevention, 2004, Vol.13 (1), p.132-137

2004

Link zum Volltext

Verfügbarkeit prüfen

Oral quinine pharmacokinetics and dietary salt intake

European journal of clinical pharmacology, 2001-05, Vol.57 (2), p.111-113

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats

Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132)

Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study

Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience

A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience

Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC)

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers

Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience

Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience

IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results

Inhibition of carcinogenesis by tea

Urinary and Plasma Levels of Resveratrol and Quercetin in Humans, Mice, and Rats after Ingestion of Pure Compounds and Grape Juice

Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability

Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract

Oral quinine pharmacokinetics and dietary salt intake

Suchergebnisse filtern